Dako expands companion diagnostics collaboration with Amgen

Published: 24-Mar-2015
Research & Development Analysis

Will pool their knowledge of drug diagnostic R&D and companion diagnostics


Denmark-based Dako, a division of Agilent Technologies since 2012 and a provider of cancer diagnostics, has signed a new Master Collaboration Agreement with US biotechnology company Amgen.

The financial details of the agreement were not disclosed.

The companies said the expanded partnership would allow them to share their expertise in drug-diagnostic research and development and in companion diagnostic products.

They added that the collaboration is important for personalised medicine, where targeted treatments and companion diagnostics can help identify patients for whom a particular treatment may work, leading to improved patient care and more manageable healthcare costs.

  • Companies:
  • Dako Denmark A/S
  • Amgen
See more

You may also like

Research & Development

Oxford Nanopore gets cash injection

Read more
Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology

Trending Articles

  1. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  2. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
  3. Kynos Therapeutics’ KMO inhibitor demonstrates safety and tolerability in Phase I study The lead drug candidate, KNS366, demonstrated its safety and tolerability in healthy adult participants in a Phase I trial
  4. Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Oxford Nanopore gets cash injection

Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology
Research & Development

Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Immatics to receive $30 million upfront and potentially more than $1 billion in milestone payments plus royalties
Research & Development

Biocartis and Amgen sign a RAS biomarker testing collaboration in Europe

Biocartis, an innovative molecular diagnostics company, has signed a new collaboration agreement with Amgen, a leading biotechnology company
Research & Development

Teijin Pharma and Amgen to jointly research and develop new therapy for kidney diseases

Teijin Pharma Limited has entered into a collaboration and license agreement with a leading biotechnology company, Amgen, regarding research and development of new therapeutic agents for kidney diseases and disorders
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Regulatory

Hyperparathyroidism - etelcalcetide

Kidney dialysis patients often develop secondary hyperparathyroidism (SHPT), which can cause additional health issues in those with end-stage disease
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now